Literature DB >> 27118747

Newborn with severe epidermolysis bullosa: to treat or not to treat?

Martin Lehmann Boesen1, Anette Bygum2, Jens Michael Hertz3, Gitte Zachariassen4.   

Abstract

Epidermolysis bullosa (EB) is an inherited skin disease with four main subtypes that cannot be distinguished clinically at birth. All subtypes may present with widespread life-threatening blisters and fragile skin, making treatment and handling of the newborn with EB challenging. The prognosis of EB depends on the subtype, and therefore maximum treatment is necessary until the final diagnosis is known. In this case, it took 2 weeks before a final diagnosis was reached. In the meantime, we had several ethical discussions on the treatment level. The most important issues were management of pain and nutrition. For immediate pain relief, intranasal fentanyl worked best and gabapentin was successfully used for chronic pain. The feeding difficulties were handled first by a nasogastric feeding tube. Later a normal feeding bottle proved to be adequate. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27118747      PMCID: PMC4854150          DOI: 10.1136/bcr-2016-214727

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

1.  Long-term follow-up of patients with Herlitz-type junctional epidermolysis bullosa.

Authors:  W Y Yuen; J C Duipmans; B Molenbuur; I Herpertz; J M Mandema; M F Jonkman
Journal:  Br J Dermatol       Date:  2012-07-05       Impact factor: 9.302

Review 2.  Overview of epidermolysis bullosa.

Authors:  Daisuke Sawamura; Hajime Nakano; Yasushi Matsuzaki
Journal:  J Dermatol       Date:  2010-03       Impact factor: 4.005

3.  [Epidermolysis bullosa simplex Dowling-Meara].

Authors:  Mimoza Frangu; Tobias Gedde-Dahl; Henrik Verder
Journal:  Ugeskr Laeger       Date:  2006-11-27

4.  Three severe cases of EBS Dowling-Meara caused by missense and frameshift mutations in the keratin 14 gene.

Authors:  Matthias Titeux; Juliette Mazereeuw-Hautier; Smaïl Hadj-Rabia; Catherine Prost; Laure Tonasso; Sylvie Fraitag; Yves de Prost; Alain Hovnanian; Christine Bodemer
Journal:  J Invest Dermatol       Date:  2006-04       Impact factor: 8.551

5.  The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB.

Authors:  Jo-David Fine; Robin A J Eady; Eugene A Bauer; Johann W Bauer; Leena Bruckner-Tuderman; Adrian Heagerty; Helmut Hintner; Alain Hovnanian; Marcel F Jonkman; Irene Leigh; John A McGrath; Jemima E Mellerio; Dedee F Murrell; Hiroshi Shimizu; Jouni Uitto; Anders Vahlquist; David Woodley; Giovanna Zambruno
Journal:  J Am Acad Dermatol       Date:  2008-04-18       Impact factor: 11.527

6.  Primers for exon-specific amplification of the KRT5 gene: identification of novel and recurrent mutations in epidermolysis bullosa simplex patients.

Authors:  K Stephens; P Ehrlich; M Weaver; R Le; A Spencer; V P Sybert
Journal:  J Invest Dermatol       Date:  1997-03       Impact factor: 8.551

Review 7.  Evaluation and treatment of the newborn with epidermolysis bullosa.

Authors:  Mercedes E Gonzalez
Journal:  Semin Perinatol       Date:  2013-02       Impact factor: 3.300

8.  Oral ketamine and midazolam for pediatric burn patients: a prospective, randomized, double-blind study.

Authors:  Claudia Norambuena; Jaqueline Yañez; Viviana Flores; Pamela Puentes; Patricia Carrasco; Rodolfo Villena
Journal:  J Pediatr Surg       Date:  2013-03       Impact factor: 2.545

9.  Oral ketamine for children with chronic pain: a pilot phase 1 study.

Authors:  Amy-Lee Bredlau; Michael P McDermott; Heather R Adams; Robert H Dworkin; Charles Venuto; Susan G Fisher; James G Dolan; David N Korones
Journal:  J Pediatr       Date:  2013-02-10       Impact factor: 4.406

Review 10.  Multicentre consensus recommendations for skin care in inherited epidermolysis bullosa.

Authors:  May El Hachem; Giovanna Zambruno; Eva Bourdon-Lanoy; Annalisa Ciasulli; Christiane Buisson; Smail Hadj-Rabia; Andrea Diociaiuti; Carolina F Gouveia; Angela Hernández-Martín; Raul de Lucas Laguna; Mateja Dolenc-Voljč; Gianluca Tadini; Guglielmo Salvatori; Cristiana De Ranieri; Stephanie Leclerc-Mercier; Christine Bodemer
Journal:  Orphanet J Rare Dis       Date:  2014-05-20       Impact factor: 4.123

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.